NCT06577532View on ClinicalTrials.gov

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

August 31, 2027

Conditions
Pancreatic NeoplasmsOther Solid Tumors
Interventions
DRUG

ABO2102

mRNA encoding mutant KRAS neoantigens, administrated intramuscularly

DRUG

Toripalimab

Anti-PD-1 antibody, administered intravenously

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Suzhou Abogen Biosciences Co., Ltd.

INDUSTRY

lead

Ruijin Hospital

OTHER